Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

“Despite advancements in the treatment landscape for non-small cell lung cancer, there remains a high unmet need for new approaches that can safely extend patients’ lives,” Dr. Ina Nordman, who ...

Key Phase III Trials in NSCLC : Ivonescimab monotherapy vs ... improving and contributing to the global IO cancer treatment landscape. Breakthrough Bispecifics Enter NRDL, Paving the Way for ...

The trial enrolled patients with NSCLC that had PD-L1 expression on ... “Imfinzi has helped change the treatment landscape and achieved multiple positive phase 3 trials for patients with earlier ...

The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen ...

Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

This positions Akeso as a key innovator in next-generation cancer immunotherapy, improving and contributing to the global IO cancer treatment landscape ... locally advanced or metastatic non-squamous ...

Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline ... ivonescimab combined with AK117 for first-line ...